Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

and specific broad-spectrum antibiotics known to contribute most to antibiotic resistance (co-amoxiclav, quinolones, and cephalosporins). Secondly, a fixed amount of tax per unit of the drug.

Cephalosporins belong to a family of antibiotics ... the more we can reduce the use of broad-spectrum antibiotics such as fluoroquinolones, which is generally the mainstay of treatment for kidney ...

Credit: Getty Images. Ceftobiprole is a broad spectrum cephalosporin antibiotic. The Food and Drug Administration (FDA) has accepted the New Drug Application for ceftobiprole, an investigational ...

and specific broad-spectrum antibiotics known to contribute most to antibiotic resistance (co-amoxiclav, quinolones, and cephalosporins). Secondly, a fixed amount of tax per unit of the drug.

Patients were excluded if they had a history of an allergic reaction with or an intolerability to either cephalosporins or vancomycin, severe renal dysfunction (CL cr of <30 mL/min), hepatic ...